Physician profile
Mark Roessler
NPI 1255348900
$1,349.48
in general payments reported to CMS, 2019-2025
12 companies · $161 in 2025
The $161 reported for 2025 was less than what a typical Otolaryngology provider received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $557 · 2020: $120 · 2021: $15.08 · 2022: $68.64 · 2023: $168 · 2024: $260 · 2025: $161.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $589.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $589.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Optinose US, INC. | $414.63 | 2019-2025 | |
| Teva Pharmaceuticals USA, INC. | $235.86 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $153.98 | 2019-2025 | Dupixent |
| Genzyme Corporation | $141.18 | 2023-2025 | |
| Intersect Ent, INC. | $100.00 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $100.00 | 2019 | |
| Vifor Pharma, INC. | $85.02 | 2019 | |
| Aerin Medical INC. | $43.03 | 2025 | |
| Ambu INC. | $35.03 | 2023 | |
| Vertex Pharmaceuticals Incorporated | $16.58 | 2025 | |
| Lucid Diagnostics INC. | $12.75 | 2022 | |
| Acclarent, INC | $11.42 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Roessler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.